Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, making it the ...

The division debarred J. Solano HVAC LLC and its owner from bidding on federally funded construction projects for a period of ...

The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.

The company has partnerships with big names in aviation and manufacturing. Even so, Archer is a high-risk, high-reward bet on ...

The FDA has approved Uplizna for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive.

Archer is stacking global catalysts fast, from Tokyo to Los Angeles to Saudi Arabia, and a new powertrain revenue stream ...

Archer Aviation (NYSE:ACHR) presents an intriguing conundrum for investors, offering both enormous promise but also plenty of ...

One of the most effective ways to attract new talent is by establishing clear, accessible pathways into the trades. That’s ...

Archer Aviation Inc. (NYSE:ACHR) is one of the Best Aerospace Stocks to Buy According to Analysts. On December 9, Archer ...

In recent years, five other drugs have been approved to treat gMG, including three complement inhibitors -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – and two neonatal ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.